{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:43:33Z","timestamp":1780339413079,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although the significant strides in novel therapeutic approaches have prolonged the survival of multiple myeloma (MM) patients, the unfavorable prognosis of cytogenetically high-risk newly diagnosed MM (NDMM) remains intractable with the lack of consensus regarding the choice of maintenance regimens. Therefore, this study was initiated with the aim of examining the effectiveness of various maintenance treatments for this group of patients in jeopardy. Overall, 17 studies with 1937 high-risk NDMM patients were included in the network meta-analysis. Combination therapies involving novel drugs presented encouraging prospects in the maintenance phase, while the patients and circumstances for the application of different regimens still needed to be further distinguished and clarified. To investigate the current status of maintenance therapy of high-risk NDMM patients in clinical practice, a real-world cohort of high-risk NDMM was retrospectively incorporated 80 patients with lenalidomide maintenance and 53 patients with bortezomib maintenance, presenting the median PFS of 31.7\u00a0months and 30.4\u00a0months, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.874, HR\u2009=\u20090.966, 95% CI: 0.628\u20131.486). Collectively, this study illuminated the present constraints of conventional approaches during the maintenance phase for high-risk NDMM patients while highlighting the future potential associated with enhanced regimens integrating novel medications.<\/jats:p>","DOI":"10.1007\/s10238-024-01445-6","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T13:08:23Z","timestamp":1722949703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs"],"prefix":"10.1007","volume":"24","author":[{"given":"Xinyuan","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5389-7550","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"2","key":"1445_CR1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252\u201364.","journal-title":"Br J Haematol"},{"issue":"10272","key":"1445_CR2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"10068","key":"1445_CR3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327.","journal-title":"Lancet"},{"issue":"1","key":"1445_CR4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2010.1.489","volume":"2010","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H. Ultra high-risk myeloma. Hematol Am Soc Hematol Educ Program. 2010;2010(1):489\u201393.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"1445_CR5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548\u201367.","journal-title":"Am J Hematol"},{"issue":"19","key":"1445_CR6","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1182\/blood.2020008733","volume":"139","author":"E Zamagni","year":"2022","unstructured":"Zamagni E, Barbato S, Cavo M. How I treat high-risk multiple myeloma. Blood. 2022;139(19):2889\u2013903.","journal-title":"Blood"},{"issue":"19","key":"1445_CR7","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759\u201369.","journal-title":"N Engl J Med"},{"issue":"1","key":"1445_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K, et al. NCCN guidelines insights: multiple myeloma, version 3.2022. J Natl Compr Canc Netw. 2022;20(1):8\u201319.","journal-title":"J Natl Compr Canc Netw"},{"issue":"21","key":"1445_CR9","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","volume":"19","author":"GJ Morgan","year":"2013","unstructured":"Morgan GJ, Davies FE, Gregory WM, et al. Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013;19(21):6030\u20138.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1445_CR10","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ajh.26161","volume":"96","author":"S Goldman-Mazur","year":"2021","unstructured":"Goldman-Mazur S, Kumar SK. Current approaches to management of high-risk multiple myeloma. Am J Hematol. 2021;96(7):854\u201371.","journal-title":"Am J Hematol"},{"issue":"5","key":"1445_CR11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"21","key":"1445_CR12","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","volume":"115","author":"B Nair","year":"2010","unstructured":"Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003\u201333) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance. Blood. 2010;115(21):4168\u201373.","journal-title":"Blood"},{"issue":"3","key":"1445_CR13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","volume":"28","author":"AK Nooka","year":"2014","unstructured":"Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28(3):690\u20133.","journal-title":"Leukemia"},{"issue":"10","key":"1445_CR14","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","volume":"4","author":"F Gay","year":"2018","unstructured":"Gay F, Jackson G, Rosi\u00f1ol L, et al. Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis. JAMA Oncol. 2018;4(10):1389\u201397.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1445_CR15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"1445_CR16","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"1445_CR17","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.","journal-title":"BMJ"},{"issue":"4","key":"1445_CR18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360\u201376.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"1445_CR19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/096228029600500402","volume":"5","author":"A Gelman","year":"1996","unstructured":"Gelman A, Rubin DB. Markov chain Monte Carlo methods in biostatistics. Stat Methods Med Res. 1996;5(4):339\u201355.","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"1445_CR20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"SP Brooks","year":"1998","unstructured":"Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7(4):434\u201355.","journal-title":"J Comput Graph Stat"},{"issue":"11","key":"1445_CR21","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7\u20138","key":"1445_CR22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7\u20138):932\u201344.","journal-title":"Stat Med"},{"issue":"19","key":"1445_CR23","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782\u201391.","journal-title":"N Engl J Med"},{"issue":"3","key":"1445_CR24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301\u201310.","journal-title":"Blood"},{"issue":"1","key":"1445_CR25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57\u201373.","journal-title":"Lancet Oncol"},{"issue":"10168","key":"1445_CR26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393(10168):253\u201364.","journal-title":"Lancet"},{"issue":"34","key":"1445_CR27","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","volume":"38","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, \u0160pi\u010dka I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020;38(34):4030\u201341.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1445_CR28","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3324\/haematol.2019.226407","volume":"105","author":"S Bringhen","year":"2020","unstructured":"Bringhen S, D\u2019Agostino M, Paris L, et al. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. Haematologica. 2020;105(7):1937\u201347.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"1445_CR29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-137109","volume":"136","author":"JL Kaufman","year":"2020","unstructured":"Kaufman JL, Laubach JP, Sborov D, et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of GRIFFIN after 12 months of maintenance therapy. Blood. 2020;136(Suppl 1):45\u20136.","journal-title":"Blood"},{"issue":"10218","key":"1445_CR30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132\u201341.","journal-title":"Lancet"},{"issue":"12","key":"1445_CR31","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3324\/haematol.2019.240374","volume":"105","author":"S Zweegman","year":"2020","unstructured":"Zweegman S, Stege CAM, Haukas E, et al. Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126\/NMSG 21.13 trial. Haematologica. 2020;105(12):2879\u201382.","journal-title":"Haematologica"},{"issue":"26","key":"1445_CR32","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","volume":"137","author":"T Facon","year":"2021","unstructured":"Facon T, Venner CP, Bahlis NJ, et al. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2021;137(26):3616\u201328.","journal-title":"Blood"},{"issue":"12","key":"1445_CR33","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1705\u201320.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1445_CR34","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(10):1378\u201390.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1445_CR35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","volume":"24","author":"D Dytfeld","year":"2023","unstructured":"Dytfeld D, Wr\u00f3bel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(2):139\u201350.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1445_CR36","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","volume":"137","author":"A Larocca","year":"2021","unstructured":"Larocca A, Bonello F, Gaidano G, et al. Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027\u201336.","journal-title":"Blood"},{"issue":"18","key":"1445_CR37","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol L, Oriol A, R\u00edos R, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142(18):1518\u201328.","journal-title":"Blood"},{"issue":"4","key":"1445_CR38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"11","key":"1445_CR39","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1445_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00390-3","volume":"11","author":"MA Baertsch","year":"2021","unstructured":"Baertsch MA, Mai EK, Hielscher T, et al. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2021;11(1):1.","journal-title":"Blood Cancer J"},{"issue":"14","key":"1445_CR41","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/cncr.34778","volume":"129","author":"N Bumma","year":"2023","unstructured":"Bumma N, Dhakal B, Fraser R, et al. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023;129(14):2179\u201391.","journal-title":"Cancer"},{"issue":"3","key":"1445_CR42","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/leu.2017.256","volume":"32","author":"R Chakraborty","year":"2018","unstructured":"Chakraborty R, Muchtar E, Kumar SK, et al. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia. 2018;32(3):712\u20138.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"1445_CR43","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2022-162741","volume":"140","author":"H Hassoun","year":"2022","unstructured":"Hassoun H, Jacobus SJ, Richardson PG, et al. Multivariable analyses of prognostic factors for progression-free survival (PFS) and complete response (CR) with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial. Blood. 2022;140(Suppl 1):4834\u20138.","journal-title":"Blood"},{"issue":"25","key":"1445_CR44","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(25):2901\u201312.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1445_CR45","doi-asserted-by":"crossref","first-page":"10144","DOI":"10.1182\/blood-2022-160451","volume":"140","author":"N Callander","year":"2022","unstructured":"Callander N, Silbermann R, Kaufman J, et al. Analysis of transplant-eligible patients (pts) who received frontline daratumumab (DARA)-based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCA) in the GRIFFIN and MASTER studies. Blood. 2022;140(Suppl 1):10144\u20137.","journal-title":"Blood"},{"issue":"4","key":"1445_CR46","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/bjh.19353","volume":"204","author":"A Hwang","year":"2024","unstructured":"Hwang A, Hayden P, Pawlyn C, McLornan D, Garderet L. The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: considerations on behalf of the chronic malignancies working party of the EBMT. Br J Haematol. 2024;204(4):1159\u201375.","journal-title":"Br J Haematol"},{"issue":"24","key":"1445_CR47","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946\u201355.","journal-title":"J Clin Oncol"},{"key":"1445_CR48","doi-asserted-by":"crossref","first-page":"1028571","DOI":"10.3389\/fonc.2023.1028571","volume":"13","author":"Z Zhuang","year":"2023","unstructured":"Zhuang Z, Tian Y, Shi L, et al. Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China. Front Oncol. 2023;13:1028571.","journal-title":"Front Oncol"},{"issue":"13","key":"1445_CR49","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","volume":"120","author":"MV Mateos","year":"2012","unstructured":"Mateos MV, Oriol A, Mart\u00ednez-L\u00f3pez J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012;120(13):2581\u20138.","journal-title":"Blood"},{"issue":"34","key":"1445_CR50","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28(34):5101\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1445_CR51","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S2666-6367(22)00174-9","volume":"28","author":"N Bumma","year":"2022","unstructured":"Bumma N, Dhakal B, Fraser R, et al. Impact of bortezomib-based vs. lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Transplant Cell Ther. 2022;28(3):S12\u20133.","journal-title":"Transplant Cell Ther."},{"issue":"Suppl 1","key":"1445_CR52","doi-asserted-by":"crossref","first-page":"10111","DOI":"10.1182\/blood-2022-170869","volume":"140","author":"S Naqvi","year":"2022","unstructured":"Naqvi S, Fatima S, Asghar N, et al. Post autologous stem cell transplant maintenance in patients with newly diagnosed multiple myeloma: a network meta-analysis. Blood. 2022;140(Suppl 1):10111\u20133.","journal-title":"Blood"},{"issue":"5","key":"1445_CR53","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s12325-022-02083-8","volume":"39","author":"T Facon","year":"2022","unstructured":"Facon T, San-Miguel J, Dimopoulos MA, et al. Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: a systematic literature review and network meta-analysis. Adv Ther. 2022;39(5):1976\u201392.","journal-title":"Adv Ther"},{"issue":"8","key":"1445_CR54","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784\u201392.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1445_CR55","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood.2020007522","volume":"136","author":"JK Jasielec","year":"2020","unstructured":"Jasielec JK, Kubicki T, Raje N, et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020;136(22):2513\u201323.","journal-title":"Blood"},{"issue":"1","key":"1445_CR56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt LB, Tichy D, Besemer B, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2024;42(1):26\u201337.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1445_CR57","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1182\/blood-2022-159756","volume":"140","author":"E Zamagni","year":"2022","unstructured":"Zamagni E, Boccadoro M, Spencer A, et al. MajesTEC-4 (EMN30): a phase 3 trial of teclistamab+lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2022;140(Suppl 1):7289\u201391.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01445-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01445-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01445-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:25:39Z","timestamp":1732987539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01445-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01445-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study adhered to the Declaration of Helsinki and was approved by the Ethics Review Committee of the Chinese Clinical Trial Registry with an approval number of ChiECRCT20190119.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All the authors agreed to publish the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was exempted by the ethics committee due to the nature of a retrospective study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"179"}}